Optima Health PLC Notice of Results

RNS Number : 7445N

Optima Health PLC

27 November 2024

 

 

Optima Health plc

("Optima", the "Company", and, together with its subsidiaries, the "Group")

 

Notice of Half Year Results

 

LONDON, UK, 27 November 2024, Optima Health (AIM: OPT), the UK's leading provider of technology enabled corporate health and wellbeing solutions, will announce its Half Year Results for the six months ended 30 September 2024 on Wednesday 11 December 2024.

 

Jonathan Thomas, Chief Executive Officer, and Heidi Giles, Chief Financial Officer, will host an in-person briefing for analysts at 11:00am GMT on the day of the results at 1 Moorgate, London, EC2R 6EA. There will also be a live webcast and conference call with a Q&A session.

 

For more details or to attend the briefing, please contact [e-mail]

 

 

Enquiries

 

Optima Health Jonathan Thomas, CEO Heidi Giles, CFO   [phone] [e-mail] Nominated Adviser and Corporate Broker Panmure Liberum Limited Emma Earl / Will Goode/ Mark Rogers Rupert Dearden     [phone]   UK Financial PR Adviser ICR Consilium Mary-Jane Elliott / Angela Gray / Chris Welsh   [e-mail]

 

 

About Optima Health

Optima Health is the UK's leading provider of occupational health and wellbeing services, directly influencing and improving people's lives for 25 years. Optima Health's incredible team of professionals quickly and effectively encapsulate client's needs, supporting organisations of all shapes and sizes. Through tailored solutions and innovative systems, Optima Health offers unparalleled clinical expertise to its clients. These solutions ensure that processes are simple and allow its clients to spend more time focusing on their employees driving a healthy, high-performing workplace. For more information visit www.optima health.co.uk

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NORFLFSRLALRFIS